CATALYST BIOSCIENCES INC (CBIO)       0.5372  -0.01 (-2.33%)

0.5372  -0.01 (-2.33%)

US14888D2080 - Common Stock

CATALYST BIOSCIENCES INC0.5372

NASDAQ:CBIO (12/6/2022, 7:26:02 PM)-0.01 (-2.33%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-30 2022-11-30/dmh Earnings (Next) 03-29 2023-03-29
Ins Owners 0.43% Inst Owners 24.56%
Market Cap 16.92M Shares 31.49M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 77.78
IPO 04-12 2006-04-12

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CBIO Daily chart

Company Profile

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 45 full-time employees. The company went IPO on 2006-04-12. The firm is focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems. The firm's product candidates consist of the coagulation-related assets marzeptacog alfa (activated) (MarzAA), dalcinonacog alfa (DalcA), and CB 2679d-GT. The firm's product MarzAA is a subcutaneously (SQ) administered next generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders. The firm's DalcA is a next generation SQ Factor IX product candidate for the prophylactic treatment of individuals with hemophilia B. Its CB 2679d-GT is an Adeno-associated virus (AAV)-based gene therapy construct harboring the DalcA sequence. The firm's SQ product candidates demonstrate a prolonged duration of activity enabling them to provide continuous therapeutic levels.

Company Info

CATALYST BIOSCIENCES INC

611 Gateway Blvd Ste 710

South San Francisco CALIFORNIA 94080

P: 16508710761.0

CEO: Nassim Usman

Employees: 45

Website: http://www.catalystbiosciences.com/

CBIO News

News Image3 months ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting Wednesday with an overview of the biggest pre-market stock movers this morning and the news moving those shares!

News Image3 months ago - Catalyst Biosciences, Inc.Catalyst Biosciences, Inc. Announces September 21, 2022 as the Ex-Dividend Date for Special Cash Dividend of $1.43 per share

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”) today...

News Image4 months ago - Catalyst Biosciences, Inc.Catalyst Biosciences, Inc. Announces Dismissal of JDS1 Litigation

Company to Announce a Record Date for Initial Distribution in Due Course...

News Image4 months ago - JDS1, LLCJDS1, LLC Terminates Proxy Contest at Catalyst’s 2022 Annual MeetingNews Image4 months ago - Catalyst Biosciences, Inc.Catalyst Biosciences Announces Withdrawal of JDS1 Nominations to the Board

Encourages Stockholders to Vote on the WHITE Proxy Card...

News Image4 months ago - Catalyst Biosciences, Inc.Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Catalyst Stockholders Vote “FOR” All of the Company’s Nominees on the WHITE Proxy Card

ISS and Glass Lewis Highlight That Stockholders Are Best Served by Allowing the Incumbent Board to Pursue Its Cash Distribution Plan Catalyst Urges...

CBIO Twits

Here you can normally see the latest stock twits on CBIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example